

1 **Liver fibrosis assessed using non-invasive markers and genetic polymorphisms (*PNPLA3* and *TM6SF2*)**  
2 **predisposing to liver fibrosis, is associated with hospitalization or death from heart failure: a prospective**  
3 **UK Biobank study**

4  
5 Theresa J Hydes PhD, [theresa.hydes@liverpool.ac.uk](mailto:theresa.hydes@liverpool.ac.uk);<sup>1,2,3\*</sup> Oliver J Kennedy PhD, [ojk@doctors.org.uk](mailto:ojk@doctors.org.uk);<sup>4\*</sup> Kate  
6 Glyn-Owen MD, [k.glyn-owen@soton.ac.uk](mailto:k.glyn-owen@soton.ac.uk);<sup>4</sup> Ryan Buchanan PhD, [ryan.buchanan@soton.ac.uk](mailto:ryan.buchanan@soton.ac.uk);<sup>4,6</sup> Julie  
7 Parkes PhD, [jules@soton.ac.uk](mailto:jules@soton.ac.uk);<sup>4</sup> Daniel J Cuthbertson PhD, [dan.cuthbertson@liverpool.ac.uk](mailto:dan.cuthbertson@liverpool.ac.uk);<sup>1,2,3</sup> Paul  
8 Roderick MD, [pjr@soton.ac.uk](mailto:pjr@soton.ac.uk);<sup>4</sup> Christopher D Byrne PhD, [c.d.byrne@soton.ac.uk](mailto:c.d.byrne@soton.ac.uk);<sup>5,6</sup>

9  
10 <sup>1</sup>Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences,  
11 Faculty of Health & Life Sciences, University of Liverpool

12 <sup>2</sup>University Hospital Aintree, Liverpool University Hospitals NHS Foundation Trust, Liverpool

13 <sup>3</sup>Liverpool Centre for Cardiovascular Science, University of Liverpool

14 <sup>4</sup>School of Primary Care, Population Sciences and Medical Education, University of Southampton

15 <sup>5</sup>Nutrition and Metabolism, Human Development and Health, Faculty of Medicine, University of  
16 Southampton

17 <sup>6</sup>Southampton National Institute for Health and Care Research, Biomedical Research Centre, University  
18 Hospital Southampton

19  
20 \* TJH and OJK are joint first authors

\* PR and CDB are joint senior authors

21  
22 **Word count**

23 4716

24  
25 **Funding**

26 CDB is supported in part by the Southampton NIHR Biomedical Research Centre (NIHR203319), UK.

27  
28 **Disclosures**

29 None

30  
31 **Acknowledgements**

32 None

33  
34 **Key words**

1 Heart failure, fibrosis, liver cirrhosis, non-alcoholic fatty liver disease, alcohol

2 **Address for correspondence**

3 Theresa J Hydes<sup>1</sup> or Christopher D Byrne<sup>2</sup>

4 <sup>1</sup>Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences,  
5 Faculty of Health and Life Sciences, University of Liverpool, Clinical Sciences Building (3rd floor)  
6 University Hospital Aintree, L9 7AL

7 <sup>2</sup>Southampton National Institute for Health and Care Research Biomedical Research Centre, Southampton  
8 Centre for Biomedical Research, Mailpoint 218, Southampton General Hospital, Tremona Road,  
9 Southampton, SO16 6YD

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

1 **ABSTRACT**

2

3 **Background** Aside from liver related complications, non-alcoholic fatty liver disease (NAFLD) and  
4 alcohol-related liver disease (ArLD) are associated with an increased risk of cardiovascular disease  
5 (CVD). Liver fibrosis, determined via histology and non-invasive serum fibrosis markers, is associated  
6 with cardiovascular events. The association between liver fibrosis and heart failure, and the  
7 relationship between *PNPLA3* rs738409 and *TM6SF2* rs58542926 and heart failure is of particular  
8 interest, given the known associations of these genetic polymorphisms with increased risk of liver  
9 fibrosis and decreased risk of coronary artery disease.

10 **Methods** Using data from the UK Biobank (UKBB), we examined the relationship between liver  
11 fibrosis, determined using non-invasive markers (NAFLD fibrosis score, Fibrosis-4 (FIB-4) and AST to  
12 platelet ratio index (APRI score)) and hospitalization or death from heart failure in 413,860 people.  
13 Participants were followed up prospectively via electronic linkage to hospital and death records.  
14 Cox-regression estimated the hazard ratios (HR) for death or admission with heart failure. The  
15 effects of *PNPLA3* and *TM6SF2* on the association between liver fibrosis and incident heart failure  
16 were estimated in an analysis stratified by genotype and by testing for an interaction between  
17 genotype and liver fibrosis using a likelihood ratio test.

18 **Results** 12,527 incident cases of heart failure occurred over a median of 10.7 years. Liver fibrosis,  
19 determined by single or combination non-invasive tests, was associated with an increased risk of  
20 hospitalization or death from heart failure; multivariable adjusted high risk NFS score HR 1.59 [1.45-  
21 1.76],  $p < 0.0001$ , FIB-4 HR 1.69 [1.55-1.84],  $p < 0.0001$ , APRI HR 1.85 [1.56-2.19],  $p < 0.0001$ , combined  
22 fibrosis scores HR 1.90 [1.44-2.49],  $p < 0.0001$ ). These associations persisted for people with NAFLD or  
23 harmful alcohol consumption. Polymorphisms linked to liver fibrosis (*PNPLA3* rs738409 GG and  
24 *TM6SF2* rs58542926 TT) further amplified the positive association between non-invasive liver  
25 fibrosis markers and heart failure. A statistically significant interaction was found between *PNPLA3*  
26 rs738409, FIB-4, APRI score and heart failure.

27 **Conclusion** Liver fibrosis, determined via non-invasive tests, is associated with an increased risk of  
28 hospitalization/death from heart failure in a general population cohort with mixed etiologies of  
29 chronic liver disease, including individuals with NAFLD and harmful alcohol consumption. Genetic  
30 polymorphisms associated with increased risk of liver fibrosis further increased the risk of heart  
31 failure. These findings have important mechanistic, clinical, and public health implications.

32

33

34

## 1 BACKGROUND

2

3 Liver disease is a major public health problem globally.<sup>1</sup> In addition to adverse liver related outcomes  
4 (hepatic failure, transplant, liver cancer and death), liver disease is a significant risk factor for  
5 adverse cardiovascular outcomes.<sup>2</sup> An increasing prevalence of obesity and type 2 diabetes  
6 (diabesity) has resulted in the emergence of non-alcoholic fatty liver disease (NAFLD) as the leading  
7 cause of chronic liver disease. Morbidity and mortality associated with NAFLD is projected to  
8 increase exponentially between now and 2030.<sup>3</sup> NAFLD is a multisystem disease that increases risk  
9 of a myriad of other diseases beyond the liver, i.e. significant extra-hepatic complications.<sup>4</sup> Indeed  
10 cardiovascular disease (CVD) is the leading cause of mortality for people with NAFLD,<sup>5</sup> independent  
11 of shared cardiometabolic risk factors.<sup>4,6</sup> Alcohol-related liver disease (ArLD) is the leading cause of  
12 cirrhosis worldwide.<sup>1</sup> Similarly higher alcohol consumption is associated with an elevated risk of CVD  
13 with a roughly linear association with increased risk of stroke, coronary disease (excluding  
14 myocardial infarction), heart failure and hypertensive heart disease.<sup>7</sup> Due to the synergistic effect of  
15 metabolic risk factors and alcohol consumption, Europe and North America are currently at high risk  
16 of increased liver disease cases in the next few decades.<sup>1</sup> A potential link between NAFLD and heart  
17 failure is a rapidly proliferating research area and an association has been confirmed in several  
18 studies.<sup>6,8-10</sup> A recent meta-analysis of 11 longitudinal cohort studies, including multi-national  
19 aggregate data on 11,242,231 middle-aged individuals with 97,716 cases of incident heart failure  
20 over a median of 10 years, confirmed that NAFLD is an independent risk factor for incident heart  
21 failure (pooled random-effects hazard ratio 1.50, 95% confidence interval 1.34-1.67,  $p < 0.0001$ ),  
22 although the authors were not able to examine the association between liver fibrosis and heart  
23 failure.<sup>10</sup>

24 Liver fibrosis is a key histological stage associated with adverse liver-related clinical outcomes for all  
25 etiologies of chronic liver disease.<sup>11,12</sup> Liver fibrosis is also strongly associated with extra-hepatic  
26 complications, in particular cardiovascular disease (CVD).<sup>6,13,14</sup> This association remains irrespective  
27 of whether fibrosis is determined histologically<sup>6</sup> or with non-invasive markers.<sup>13,14</sup> Very few studies  
28 have examined the relationship between liver fibrosis and heart failure however. This is a highly  
29 pertinent question, both from a clinical and pathophysiological perspective, given the rising  
30 incidence of liver fibrosis in the population and the high levels of morbidity, mortality and health  
31 care costs associated with heart failure.

32 Multiple gene wide association studies (GWAS) and candidate gene studies have identified an  
33 association between single nuclear polymorphisms (SNP) in two specific genes: patatin-like  
34 phospholipase domain-containing 3 (*PNPLA3*) (rs738409 c.444 C>G, encoding Ile148Met (I148M))

1 and transmembrane 6 superfamily member 2 (*TM6SF2*) (rs58542926 c.449 C>T, p.Glu167Lys,  
2 E167K)) with more advanced liver disease, particularly fibrosis. Thus, those subjects with the GG  
3 homozygous variant for *PNPLA3* and the TT homozygous variant for *TM6SF2* are at the highest risk of  
4 liver fibrosis. This association is valid in people with NAFLD,<sup>15-18</sup> and other etiologies of chronic liver  
5 disease,<sup>19</sup> including ArLD,<sup>20-22</sup> and chronic hepatitis C.<sup>23</sup> Genetic analysis can be used to identify  
6 patients at high risk of liver fibrosis without the inherent issue of metabolic/environmental risk  
7 factors confounding any association between liver fibrosis and extra-hepatic complications.  
8 Considering the paradox whereby the SNPs rs738409 (*PNPLA3*) and rs58542926 (*TM6SF2*) are  
9 associated with liver fibrosis, and yet confer protection against CVD,<sup>24</sup> the relationship between  
10 these genetic variants and incident heart failure is of great interest. These data would help establish  
11 whether any causal relationship (or not) exists between liver and cardiac fibrosis and would  
12 influence clinical practice.

13 Using data from the UK Biobank (UKBB), we aimed to examine the relationship between liver  
14 fibrosis, determined using both non-invasive markers of liver fibrosis and genetic markers (rs738409  
15 and rs58542926 SNPs), and incident heart failure. We also aimed to test whether there was any  
16 modifying influence or interaction, between these genetic markers and the liver fibrosis scores  
17 affecting the risk of incident heart failure, in a general population cohort.

18

## 19 **METHODS**

20

### 21 **Study population**

22 The UKBB is a longitudinal, prospective study and an unparalleled national health resource aimed at  
23 improving and preventing chronic disease through the identification of genetic and behavioral  
24 determinants of health in middle-aged and older adults.<sup>25</sup> Over 500,000 individuals, aged 40-69  
25 years, identified from National Health Service registers agreed to participate and were recruited  
26 between 2006 to 2010. At a baseline assessment visit, participants completed a touch-screen  
27 questionnaire about their sociodemographic, lifestyle and medical history. Self-reported doctor  
28 diagnosed medical conditions and medication history were verified and coded by nurses during a  
29 face-to-face interview.<sup>26</sup> The volunteers underwent a physical examination including anthropometric  
30 measurements and provided non-fasting blood and urine samples. Genome-wide genotyping was  
31 performed on 488,377 participants using the UK Biobank Axiom Array. UKBB participants gave their  
32 consent to be continually followed-up through linkage to electronic health records, including records  
33 from the Office for National Statistics and the Registrar General's Office (death records and cancer  
34 registers) in addition to hospital records, held by the Department of Health's Hospital Episode

1 Statistics and the Scottish Morbidity Records (<http://content.digital.nhs.uk/services>). At the time of  
2 analysis, mortality data were available up to January 2023. Ethical approval was granted by the  
3 Northwest Multi-Centre Research Ethics Committee.

4

#### 5 **Inclusion and exclusion criteria**

6 All UK Biobank participants were initially included. Exclusions were made for individuals with a  
7 baseline ICD code or self-reported UKBB code for heart failure (**Supplementary Methods**), and those  
8 for whom we did not have sufficient data to calculate non-invasive markers of fibrosis, including the  
9 fibrosis-4 (FIB-4) score,<sup>27</sup> NAFLD fibrosis score (NFS),<sup>28</sup> or aspartate transaminase to platelet ratio  
10 index (APRI) (**Box 1**).<sup>29</sup>

11

12 **Box 1.** Non-invasive fibrosis markers and their calculation

<b>Fibrosis-4 index (FIB-4)</b>	$\text{Age [years]} \times \text{AST [U/l]} / (\text{platelets [x10}^9\text{/L]} \times \sqrt{\text{ALT [U/l]}})$
<b>NAFLD fibrosis score (NFS)</b>	$-1.675 + 0.037 \times \text{Age [years]} + 0.094 \times \text{BMI [kg/m}^2\text{]} + 1.13 \times (\text{IFG or diabetes [yes=1, no=0]}) + 0.99 \times \text{AST [U/l]} / \text{ALT [U/l]} - 0.013 \times \text{platelets [10}^9\text{/L]} - 0.66 \times \text{albumin [g/dl]}$
<b>AST to platelet index (APRI)</b>	$[(\text{AST [U/L]} / \text{AST upper limit of normal [U/L]}) / \text{platelet [x10}^9\text{/L]}] \times 100$

13

#### 14 **Ascertainment of exposure**

15 Advanced fibrosis was defined as FIB-4 score > 2.67, NFS > 0.676 or APRI score  $\geq$  1.0. Advanced  
16 fibrosis was excluded if there was a FIB-4 score < 1.3 (< 2.0 if  $\geq$  65 years), NFS < -1.455 (<0.12 if  $\geq$  65  
17 years) or APRI < 1.0. Participants not falling into these groups were placed in an indeterminate  
18 fibrosis group.

19

#### 20 **Primary outcome**

21 The primary outcome for this study was incident heart failure, defined as an ICD-9 (428.0-428.9) or  
22 ICD-10 (I50.0-I50.9) code for a new diagnosis of heart failure (i.e., a hospital admission), or heart  
23 failure given as the primary, and or secondary cause of death on the death certificate. We  
24 investigated a combination of non-fatal and fatal events given the low overall number of heart  
25 failure related deaths. Where a participant may have had multiple admissions with heart failure, the  
26 first event was included.

27

## 1 **Statistical analysis**

2 Baseline characteristics are presented as percentages, and continuous data are presented using the  
3 median and interquartile range (IQR). Univariate and multivariable Cox proportional hazards models  
4 were used to calculate the association of elevated non-invasive markers of liver fibrosis on heart  
5 failure to determine hazard ratios (HR), 95% confidence intervals (CIs) and statistical significance.  
6 Non-cases were censored at the date of loss to follow-up, date of death or the end of follow-up.  
7 Data on confounding factors was gathered from the baseline assessment and pre-selected factors  
8 identified to be clinically relevant from the literature were entered into multivariable regression  
9 models. **Model 1** was adjusted for age, sex, ethnicity and Townsend deprivation index (an address-  
10 based metric of socioeconomic status based on car ownership, home ownership, employment and  
11 over-crowding).<sup>30</sup> **Model 2** was additionally adjusted for alcohol (weekly grams; continuous) and  
12 smoking status (never, previous, current). **Model 3** was adjusted for the above factors, in addition to  
13 metabolic factors including: type 2 diabetes, baseline waist circumference, hypertension, and  
14 dyslipidemia. **Model 4** was additionally adjusted for a prior history of acute coronary syndrome,  
15 valvular disease, cardiomyopathy and arrhythmias (identified by the participant, or coded for in  
16 hospital records). Full definitions are provided in the **Supplementary Methods**. The linearity of the  
17 effect of each continuous variable in the adjusted models (i.e., weekly alcohol grams, age, waist  
18 circumference, deprivation) was determined using univariate Cox hazard regression with penalized  
19 splines. Where a Wald-type test using the nonlinear coefficient estimates indicated significant non-  
20 linearity, splines were used in further analyses. The validity of the proportional hazards assumption  
21 for each variable was determined by examining correlations between scaled Schoenfeld residuals  
22 and time. The statistical package used was R. The Strengthening the Reporting of Observational  
23 Studies in Epidemiology (STROBE) guidelines were followed in reporting this study.<sup>31</sup>

## 24 25 **Sensitivity analyses**

26 We performed two sensitivity analyses; the first excluding individuals who were either former, or  
27 harmful drinkers (women drinking over 280 grams per week, or men drinking > 400 grams per  
28 week), and the second excluding people with baseline cardiovascular disease, including heart failure,  
29 acute coronary syndrome, valve disease, cardiomyopathy, arrhythmias.

## 30 31 **Subgroup analyses**

32 We performed the same analysis in participants with a baseline diagnosis of NAFLD, defined as  
33 having an ICD-9 (571.8) or ICD-10 (K75.8, K76.0) code indicating NAFLD, or a hepatic steatosis index  
34 (HSI) score > 30,<sup>32</sup> in the absence of another etiology of chronic liver disease; and those with harmful

1 alcohol consumption defined as drinking more than 280g of alcohol per week (women), or over 400g  
2 of alcohol per week (men), or having an ICD code for alcohol related liver disease, or and ICD code  
3 for alcohol dependency (see **Supplementary Methods** for definitions). In addition, we analyzed the  
4 relationship between non-invasive markers of liver fibrosis and heart failure in people living with or  
5 without obesity and those living with or without type 2 diabetes (see **Supplementary Methods** for  
6 definitions).

7

## 8 **Gene effect analysis**

9 In total 488,377 individuals were genotyped for up to 812,428 variants using DNA extracted from  
10 blood samples on either the UKBB Axiom array (438,427 participants) or the UK BiLEVE Axiom array  
11 (49,950 participants).<sup>33</sup> We investigated the effect of the two SNPs of interest: rs738409 (*PNPLA3*)  
12 (chromosome 22, location 44324727) and rs58542926 (*TM6SF2*) (chromosome 19, location  
13 19268740) that are known to be associated with liver fibrosis. We assessed the association between  
14 liver fibrosis determined via non-invasive tests and hospitalization, or death, from heart failure  
15 stratified by these genotypes. The interaction between non-invasive serum fibrosis scores and  
16 genotype in relation to heart failure risk was evaluated using a likelihood ratio test. This test  
17 determined whether the inclusion of an interaction term in a Cox model estimating the association  
18 between fibrosis score and heart failure significantly improved the model fit.

19

## 20 **RESULTS**

21

### 22 **Study population and baseline demographics**

23 All 502,506 participants within the UKBB were included. Following the exclusion of individuals with a  
24 diagnosis of heart failure at baseline, or insufficient data to calculate the NFS, FIB-4 or APRI score,  
25 the final study population consisted of 413,860 participants (**Figure 1**). Baseline demographics are  
26 shown in **Table 1**. The baseline characteristics of individuals excluded did not differ significantly to  
27 the overall UKBB population (**Supplementary Table 1**). In total 1.3% (n=5400), 2.2% (n=9226) and  
28 0.5% (n=2169) of people in the UKBB had evidence of liver fibrosis according to the NFS, FIB-4 and  
29 APRI scores respectively.

30 We attempted to determine an etiology of liver disease for all participants with raised non-invasive  
31 markers (**Table 2, Supplementary Table 2**). Frequencies of NAFLD were 56.2%, 31.3% and 30.0%,  
32 and frequencies of ArLD were 12.9%, 18.0% and 32.0% for people with a raised NFS score, FIB-4  
33 score and APRI score respectively.

34

### 35 **Association between non-invasive fibrosis markers and incident heart failure**



1 The median follow-up period for combined fatal and non-fatal incident heart failure was 10.7 years.  
2 In total 12,527 cases of hospitalization or death from heart failure were recorded (96 of these were  
3 deaths) (**Table 3**). In total, 1926 (15.4%) of heart failure events occurred 12 months following an ICD  
4 code for acute coronary syndrome. Only 53 (0.4%) of people who developed heart failure also had a  
5 code for alcoholic cardiomyopathy. Elevated levels of non-invasive markers of liver fibrosis at  
6 baseline were associated with higher event rates of incident heart failure (**Table 3**).

7 *Univariate analysis.* Univariate analysis of baseline factors associated with heart failure are shown in  
8 **Supplementary Table 3**. Univariate analysis revealed that high NFS (HR 6.25 [5.81-6.73],  $p < 0.0001$ ),  
9 FIB-4 (HR 3.23 [3.00-3.49],  $p < 0.0001$ ) and APRI (HR 2.68 [2.29-3.13],  $p < 0.0001$ ) scores were  
10 associated with increased risk of incident heart failure (**Table 3**).

11 *Multivariable analysis.* Following multivariable adjustment for demographics, smoking, alcohol  
12 intake, metabolic risk factors and baseline cardiovascular disease, the NFS (HR 1.59 [1.47-1.78],  
13  $p < 0.0001$ ), FIB-4 (HR 1.69 [1.55-1.84],  $p < 0.0001$ ) and APRI scores (HR 1.85 [1.56-2.19],  $p < 0.0001$ )  
14 remained significantly associated with the development of heart failure (**Table 3, Figure 2**). A ‘dose  
15 response’ relationship by severity was observed for the NFS and FIB-4 scores.

16 *Associations with combinations of more than one high liver fibrosis score.* Where liver fibrosis was  
17 defined using combinations of non-invasive tests, people who scored ‘high’ on more than one  
18 fibrosis marker were at higher risk of developing heart failure (**Supplementary Table 4, Figure 3**).

19

## 20 **Subgroup analysis**

21 *NAFLD and harmful alcohol consumption.* We repeated this analysis in individuals whom we  
22 determined were likely to have a baseline diagnosis of NAFLD ( $n=185,002$ ) and those with evidence  
23 of current, or previous harmful alcohol consumption ( $n=49,156$ ) (see **Supplementary Table 5** for  
24 baseline demographics). For NAFLD, a high NFS (HR 1.75 [1.54-1.99],  $p < 0.0001$ ) and FIB-4 score (HR  
25 1.34 [1.14-1.57],  $p < 0.001$ ) were associated with incident heart failure following full multivariable  
26 adjustment (**Supplementary Table 6**). For people with harmful alcohol consumption all three fibrosis  
27 scores were associated with heart failure after full multivariable adjustment (NFS HR 1.98 [1.59-  
28 2.48],  $p < 0.0001$ ; FIB-4 HR 2.08 [1.74-2.49],  $p < 0.0001$ ; APRI HR 2.45 [1.90-3.16],  $p < 0.0001$ )  
29 (**Supplementary Table 7**).

30 *Type 2 diabetes and obesity status.* All three non-invasive fibrosis scores remained positively  
31 associated with heart failure death, or hospitalization, for people with and without obesity  
32 (**Supplementary Table 8**). For people with type 2 diabetes, only the NFS score remained associated  
33 with heart failure after full multivariable adjustment (**Supplementary Table 9**).

34

## 1 **Sensitivity analyses**

2 We performed a sensitivity analysis excluding individuals who were either former drinkers, or  
3 drinking > 280g/week (women), or > 400g/week (men) (**Supplementary Table 10**), and people with  
4 baseline cardiovascular disease (**Supplementary Table 11**). For both analyses, all three non-invasive  
5 markers of fibrosis continued to be significantly associated with an elevated risk of hospitalization or  
6 death from heart failure.

7

## 8 **Genetic effect analysis**

9 *TM6SF2* and *PNPLA3* SNPs. Within our study cohort for *PNPLA3*, 19,576 (4.8%) expressed the  
10 homozygous variant GG, 138,229 (33.7%) the heterozygous variant GC and 252,191 (61.5%) CC. For  
11 *TM6SF2*, 350,578 (85.6%) carried the polymorphisms CC, 56,473 (13.8%) TC and 2265 (0.6%) TT.

12 In univariate analysis, there was a trend towards an increase in the risk of incident heart failure for  
13 people with evidence of liver fibrosis determined via a non-invasive test for people with *PNPLA3* GG  
14 (high risk allele for liver fibrosis) homozygosity compared to those with the heterozygous state, or  
15 *PNPLA3* CC homozygosity (**Table 4**). Similarly, there was a trend towards amplified risk for *TM6SF2*  
16 heterozygosity compared to *TM6SF2* CC (low risk allele for liver fibrosis) for people with liver fibrosis  
17 determined via a high risk FIB-4 or APRI score at baseline (**Table 4**).

18 We incorporated interaction terms into our models to examine how *PNPLA3* and *TM6SF2* influence  
19 the relationships between fibrosis scores and heart failure risk. The interactions involving *PNPLA3*  
20 rs738409 with both FIB-4 and APRI were statistically significant. No statistically significant interaction  
21 was found with *TM6SF2* although the overall number of people with *TM6SF2* TT homozygosity and a  
22 heart failure event were very small.

23

## 24 **DISCUSSION**

25

### 26 **Summary of the main findings**

27 We have identified that liver fibrosis, determined by non-invasive tests, was associated with an  
28 elevated risk of hospitalization or death from heart failure, following full multivariable adjustment in  
29 a prospective general population cohort, unselected for any type, or risk of liver disease. This  
30 association persists for people identified to have either NAFLD or harmful alcohol consumption, and  
31 for people living with or without obesity or type 2 diabetes. Polymorphisms known to identify  
32 people at risk of liver fibrosis (*PNPLA3* rs738409 GG and *TM6SF2* rs58542926 TT) were associated  
33 with a further increase in risk of incident heart failure despite these variants having been shown to  
34 be associated with a decreased risk of coronary artery disease.<sup>24</sup> This was particularly apparent for

1 fibrosis *PNPLA3* rs738409 GG where a statistically significant interaction was found between this SNP  
2 and a high liver fibrosis score, to further amplify the risk of incident heart failure.

3

#### 4 **Comparison to the literature**

5 While few studies have directly explored the relationship between liver fibrosis and incident heart  
6 failure, data from the literature supports our findings. In the Multi-Ethnic Study of Atherosclerosis  
7 (cross-sectional, six US centres), using cardiac and liver T1-mapping magnetic resonance imaging,  
8 liver fibrosis was found to be associated with a with history of heart failure and with preclinical  
9 measures of abnormal cardiac structure and function, including left ventricular hypertrophy and  
10 myocardial fibrosis.<sup>34</sup> Using UKBB data, we recently reported that in a population of people with  
11 chronic kidney disease who also had NAFLD, elevated non-invasive markers of liver fibrosis are  
12 associated with heart failure.<sup>35</sup> Simon *et al* demonstrated in a prospective study of > 10,000 Swedish  
13 adults, followed up for a median of 13 years, that there was an increased risk of major adverse  
14 cardiovascular events in people with NAFLD.<sup>6</sup> In this study, 153 people developed congestive heart  
15 failure amongst the 1554 people with NAFLD who had non-cirrhotic fibrosis and there was an  
16 adjusted hazard ratio of 2.04 [1.66-2.51]. This study benefited from liver histological data to  
17 diagnose liver fibrosis but the overall numbers of individuals experiencing heart failure were  
18 relatively small and residual unmeasured confounding may have existed. Data from the Korean  
19 National Health Insurance identified that liver fibrosis, defined using the BARD score, in people with  
20 background NAFLD, determined using the fatty liver index, was associated with increased incident  
21 and hospitalized heart failure.<sup>36</sup> To our knowledge, no previous studies have examined the  
22 relationship between liver fibrosis and heart failure for patients in a general population, nor have  
23 any previous studies tested whether genetic polymorphisms known to identify people at risk of liver  
24 fibrosis (*PNPLA3* rs738409 GG and *TM6SF2* rs58542926 TT) modify risk of incident heart failure. This  
25 is important as these variants have previously been shown to be associated with a decreased risk of  
26 coronary artery disease.<sup>24</sup>

27 We have demonstrated that liver fibrosis, determined via non-invasive tests, in people with an  
28 alcohol-related etiology is a risk factor for heart failure. As far as we are aware, ours is also the first  
29 study to identify this association. Chronic high levels of alcohol consumption can lead to a dilated  
30 cardiomyopathy (alcoholic cardiomyopathy) characterized by cardiomegaly, reduced contractility,  
31 and disruption of myofibrillary architecture. However, only 0.4% of people with a heart failure  
32 outcome in this study had an ICD code for alcoholic cardiomyopathy and therefore there may be  
33 shared mechanistic pathways across liver disease etiologies. Furthermore, a proportion of  
34 individuals in this UKBB cohort will have heart failure related to cirrhotic cardiomyopathy. This is a

1 distinct syndrome which results from the release of proinflammatory signals and circulatory  
2 abnormalities inherent to patients with cirrhosis, in particular those with decompensated disease.  
3 We anticipate that this would only account for a minor number of cases however, given that this is a  
4 general population study recruiting healthy volunteers.  
5 We provide novel insight by exploring the association of non-invasive fibrosis markers with heart  
6 failure stratified according to genetic polymorphisms associated with liver fibrosis. *PNPLA3* rs738409  
7 GG is known to be associated with liver fibrosis in people with NAFLD.<sup>15,16</sup> Candidate gene studies  
8 from Europe have shown that the E167K variant of *TM6SF2* rs58542926 is associated with an almost  
9 two-fold increase in the risk of advanced fibrosis independent of age, diabetes, obesity, or *PNPLA3*  
10 genotype.<sup>17,18</sup> In addition to NAFLD, rs738409 for *PNPLA3* and rs58542926 for *TM6SF2* have been  
11 linked to ArLD, in particular alcohol-related cirrhosis,<sup>20–22</sup> more advanced liver disease for patients  
12 with chronic hepatitis C,<sup>23</sup> and progressive fibrosis in patients with different etiologies of chronic  
13 liver disease.<sup>19,22</sup> While these genetic variants confer increased risk for people developing more  
14 advanced liver disease, they paradoxically confer protection against cardiovascular disease.<sup>24</sup> An  
15 exome-wide association study has shown that the *TM6SF2* TT and *PNPLA3* GG genotypes are  
16 involved in hepatic production of triglyceride-rich lipoproteins, and are associated with increased  
17 risk of type 2 diabetes and a lower risk of coronary artery disease.<sup>24</sup> This protection likely results  
18 from decreased circulating levels of very low density lipoprotein (VLDL) due to reduced export of this  
19 lipoprotein from the liver, reducing the impact of the atherogenic lipoprotein phenotype that occurs  
20 with NAFLD on CVD effects.<sup>37</sup> Three metabolomic signature subgroups have been identified for  
21 NAFLD which align with CVD risk; subtype A which exhibits impaired VLDL-triglyceride secretion is  
22 associated with lower risk of CVD.<sup>38</sup> It might therefore

23

#### 24 **Clinical relevance**

25 Understanding the potential mechanistic link(s) between liver fibrosis and heart failure has  
26 significant therapeutic relevance and clinical and public health consequences. Heart failure  
27 represents a major public health problem with a globally increasing prevalence largely due to a  
28 combination of an ageing population with worsening metabolic health from the obesity epidemic;  
29 ischemic and hypertensive heart disease represent the leading causes in both men and women.<sup>40</sup>  
30 Patients' health are increasingly characterised by multimorbidity, further exacerbated by  
31 socioeconomic deprivation.<sup>41</sup> Heart failure is associated with high levels of morbidity and mortality  
32 and contributes significantly towards high health care expenditure and frequent hospital  
33 admissions.<sup>42</sup> There is predicted to be a substantial rise in population levels of liver fibrosis driven by  
34 NAFLD and alcohol consumption,<sup>1</sup> with a likely associated impact on cardiovascular disease including

1 heart failure. Early lifestyle intervention (reduced alcohol consumption, improved nutrition, and  
2 regular physical activity) and pharmacological treatments (in development), in those identified with  
3 liver fibrosis, may prevent progression towards clinically significant cardiac disease including heart  
4 failure. NAFLD-specific therapies which can reverse and prevent progression to liver fibrosis (from  
5 steatosis/steatohepatitis) are beginning to be realised.<sup>43</sup> There is however also a need to address the  
6 huge burden of undiagnosed chronic liver disease in the community.<sup>44</sup> Widespread screening of at-  
7 risk clinical groups represents a paradigm shift in clinical practice and will strain existing health care  
8 systems. Non-invasive serum markers represent a useful first line screening approach, found to be  
9 predictive of liver related morbidity in the general population.<sup>45</sup> There is not yet clear guidance as to  
10 whether patients with liver fibrosis should be screened for CVD, despite the acknowledgement that  
11 NAFLD contributes towards CVD risk and shares risk factors with CVD.<sup>46-48</sup> European guidelines for  
12 NAFLD advocate screening for CVD although they do not stipulate which assessments should occur,<sup>47</sup>  
13 whereas the American guidelines support screening for metabolic risk factors alone.<sup>46</sup> Findings from  
14 this study provide support for targeted screening for fibrosis in people with risk factors for liver  
15 disease and the adoption of a cardiometabolic multimorbidity approach to the management of  
16 people with established liver fibrosis focusing on modifiable shared risk factors.

17

### 18 **Strengths and weaknesses**

19 The UKBB is a substantial (half a million participants) prospective multi-modality dataset with nearly  
20 17 years of clinical event follow-up time. Baseline data are available to calculate multiple well  
21 validated prediction scores for risk stratification for advanced liver fibrosis, enabling us to examine  
22 the incremental risk between levels of exposure (liver fibrosis) and incident heart failure. We were  
23 additionally able to adjust for multiple potential confounders and identify incident cases of both  
24 fatal and non-fatal heart failure using linked datasets. Finally, using this specific cohort we were able  
25 to undertake a genetic association study to further validate this association and investigate the  
26 potential modifying influence of SNPs in two genes known to be associated with increased risk of  
27 liver fibrosis.

28

29 The accurate identification of liver fibrosis is challenging, with even a gold standard liver biopsy  
30 assessment subject to sampling and analysis bias.<sup>49</sup> Even with the limitations of liver biopsy, this  
31 would not be feasible, nor ethically acceptable, in the UKBB cohort without a clinical indication. Non-  
32 invasive blood-based tests achieve high negative, but low positive predictive values, although test  
33 combinations enhance diagnostic accuracy as utilized here. Simple non-invasive tests have been  
34 shown however to perform as well as histology in predicting clinical outcomes (a composite

1 endpoint of all-cause mortality and liver related events) in patients with NAFLD.<sup>50</sup> False positive  
2 results may have resulted from non-hepatic conditions for example hematological disorders or  
3 infection. Indeed, it was not possible to identify a driver of chronic liver disease in all participants  
4 with a raised fibrosis marker. It is possible that participants with a high BMI or diabetes who did not  
5 have an HSI > 30 had NAFLD, or people with reported high-risk (but not harmful) levels of alcohol  
6 intake, or a high frequency of alcohol intake without weekly gram data had ArLD, however we  
7 wanted to be conservative in our definitions to allow accurate subgroup analysis. We were reliant on  
8 ICD coding for heart failure and therefore our results fail to capture the large proportion of people  
9 with incident heart failure not associated with a hospital admission or death, i.e. less advanced  
10 disease. Admission and mortality data identifies the spectrum of heart failure associated with high  
11 levels of mortality and health care costs however, and is thus where prevention is most urgently  
12 needed.

13 Stratification of univariate associations of non-invasive markers of liver fibrosis with heart failure  
14 according to SNPs linked to liver fibrosis, revealed a trend towards an amplified risk for *PNPLA3*  
15 rs738409 GG, however the number of cases of heart failure were small for people in the group at the  
16 greatest risk (high risk non-invasive fibrosis marker and *PNPLA3* rs738409 GG) leading to wide  
17 confidence intervals. This issue was more pronounced for *TM6SF2* rs58542926 TT, where the  
18 number of events was extremely small, however a similar trend can be seen for the heterozygous  
19 state compared to *TM6SF2* rs58542926 CC where the event numbers were greater. Analysis of the  
20 interaction of *TM6SF2* rs58542926 was also likely underpowered given the low number of people  
21 with *TM6SF2* TT homozygosity. We were unable to elucidate the relationship between liver fibrosis  
22 and different phenotypes of heart failure (heart failure with either preserved or reduced ejection  
23 fraction). While patients with heart failure are at increased risk of congestive hepatopathy and  
24 ischemic hepatitis which can influence non-invasive fibrosis marker scores, fibrosis markers were  
25 calculated at baseline and individuals with pre-existing heart failure were excluded, in addition to  
26 those with underlying CVD, at the study entry point in a further sensitivity analysis which did not  
27 alter the overall findings. Sequential data on liver fibrosis markers is only available for a small  
28 proportion of UKBB participants therefore we are unable to perform time dependent regression  
29 modelling. Finally, being an observational study, we were unable to derive mechanistic insight into  
30 the link between liver fibrosis and heart failure, an area of undoubted future research relevant in the  
31 quest to identify novel therapeutic targets in the liver-cardiac axis.

32

33 **Conclusion**

1 Liver fibrosis, determined via non-invasive tests, is associated with an increased risk of  
2 hospitalization or death from heart failure in a general population where liver fibrosis was associated  
3 with a mixed etiology of chronic liver disease, including individuals with NAFLD and harmful alcohol  
4 consumption. Genetic polymorphisms associated with increased risk of liver fibrosis further  
5 increased the risk of heart failure. Stratification of risk of heart failure based on liver fibrosis  
6 genotype has also potential future relevance in an era of personalised medicine. These data provide  
7 a rationale for examining the feasibility and effectiveness of targeted community screening for  
8 undetected liver disease followed by multimorbidity assessment and aggressive cardiovascular risk  
9 factor management to prevent the development of heart failure in people with hepatic fibrosis.

10

11

**Table 1.** Baseline demographics of individuals with and without advanced liver fibrosis according to non-invasive tests (n=413,860)

	NAFLD fibrosis score			Fibrosis-4 score			AST platelet ratio index	
	Low risk	Intermediate risk	High risk	Low risk	Intermediate risk	High risk	Low risk	High risk
<b>N, (%)</b>	327,270 (79.1)	81,190 (19.6)	5400 (1.3)	271,951 (65.7)	132,683 (32.1)	9,226 (2.2)	411,691 (99.5)	2,169 (0.5)
<b>Median age, years (IQR)</b>	57 (15)	59 (8)	63 (8)	56 (16)	60 (8)	64 (7)	58 (13)	58 (12)
<b>Male (%)</b>	44.5	51.9	57.9	42.6	52.1	65.5	46.0	67.8
<b>Ethnicity (%)</b>								
White	94.8	92.4	89.9	94.3	94.4	93.3	94.3	92.4
Non white	4.8	7.1	9.3	5.4	5.2	6.1	5.3	6.8
<b>Townsend deprivation index</b>								
Median score	-2.22	-1.92	-1.19	-2.12	-2.24	-1.99	-2.16	-1.43
<b>Alcohol</b>								
Gram data available (%)	83.8	83.7	81.3	82.4	86.2	87.2	83.8	84.8
Median alcohol grams per week (IQR)	130 (192)	120 (212)	80 (221)	122 (194)	132 (206)	142 (256)	126 (196)	201 (364)
Non-drinkers (abstainers & former) (%)	7.4	9.3	15.9	8.1	7.5	9.4	7.9	9.1
Low-moderate risk drinkers (%)	44.4	46.6	48.7	46.4	42.3	38.8	44.9	33.0
High risk drinkers (%)	48.0	43.8	35.0	45.4	50.0	51.4	46.9	57.3
<b>Diabetes status</b>								
T2 diabetes (%)	2.5	15.6	58.2	5.9	5.2	10.2	5.7	17.2
Median HbA1c mmol/mol	50.9	50.2	49.3	50.8	49.3	49.2	50.3	52.8
<b>Overweight/obesity</b>								
Median BMI, kg/m <sup>2</sup> (IQR)	26.2 (5)	29.1 (7)	34.2 (11)	27 (6)	26.2 (6)	26.7 (6)	26.7 (6)	28.4 (7)
BMI < 25 kg/m <sup>2</sup> (%)	37.0	18.7	8.4	30.9	37.4	34.5	33.1	24.3
BMI 25-30 kg/m <sup>2</sup> (%)	44.1	38.2	20.2	43.1	42.0	40.6	42.7	38.3
BMI > 30 kg/m <sup>2</sup> (%)	18.8	43.1	71.4	26.1	20.6	24.9	24.2	37.5
Median WC, cm (IQR)	88 (18)	96 (20)	109 (23)	90 (18)	89 (18.2)	92 (19)	90 (19)	96.2 (20)
WC men > 102 cm, women > 88 cm (%)	25.8	47.1	74.1	32.9	26.0	31.2	30.6	44.0
<b>Lipids</b>								
Dyslipidemia (%)	53.2	60.9	79.3	56.6	51.6	58.2	55.0	64.9
Median cholesterol (mg/dL)	5.7	5.4	4.6	5.7	5.6	5.3	5.7	5.3
Median LDL (mmol/L)	3.6	3.4	2.8	3.6	3.5	3.2	3.5	3.2
Median HDL (mmol/L)	1.4	1.3	1.2	1.4	1.4	1.4	1.4	1.3
Median TG (mmol/L)	1.5	1.5	1.7	1.5	1.4	1.4	1.5	1.6
<b>Hypertension (%)</b>	27.7	39.2	67.7	29.4	31.6	45.3	30.4	46.4



<b>Smoking (%)</b>								
Never smoked	55.1	52.4	45.5	54.5	54.7	49.1	54.5	44.2
Previous smoker	33.8	37.0	44.0	33.7	36.0	40.6	34.5	39.1
Current smoker	10.6	10.0	9.6	11.3	8.8	9.7	10.5	16.0
<b>Biochemistry (Median)</b>								
ALT (IU/L)	20	19	18	20	20	22	20	68
AST (IU/L)	24	25	26	23	27	33	24	84
GGT (IU/L)	26	27	32	27	26	32	26	95
Platelets (10 <sup>6</sup> /L)	260	205	180	269	212	153	248	155
Albumin (g/L)	45	44	43	45	45	45	45	45
<b>Baseline cardiovascular events (%)</b>								
Acute coronary syndrome (%)	2.0	3.8	9.4	2.1	3.0	6.2	2.5	5.3
Valvular disease (%)	0.9	1.2	2.3	0.9	1.2	2.5	1.0	1.8
Cardiomyopathy (%)	0.1	0.2	0.4	0.1	0.1	0.2	0.1	0.3
Arrhythmias (%)	1.6	2.3	5.0	1.5	2.2	4.9	1.8	3.1

NAFLD, Non-alcoholic fatty liver disease; AST, aspartate transaminase; IQR, interquartile range; HbA1c, glycated hemoglobin; BMI, body mass index; WC, waist circumference; LDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol; TG, triglycerides; ALT, alanine transaminase; AST, aspartate transaminase; GGT gamma glutamyl transferase

**Low-moderate risk drinkers:** < 140g/week women, < 210g/week men (where frequency only data is available include people drinking < 3x/week)

**High risk drinkers:** > 140g/week women, > 210g/week men (where frequency only data is available include people drinking ≥ 3x/week)

**NAFLD fibrosis score:** low risk < -1.455 (< 0.12 if ≥ 65 yrs); intermediate risk - 1.455 – 0.676 (0.12-0.676 if ≥ 65 yrs); high risk > 0.676

**Fibrosis-4 score:** low risk < 1.3 (<2.0 if ≥ 65 yrs); intermediate risk 1.3-2.67 (2.0-2.67 if ≥ 65 yrs); high risk > 2.67

**AST platelet ratio index:** low risk < 1.0; high risk ≥ 1.0

**Table 2.** Etiology of liver disease for participants with advanced fibrosis according to non-invasive tests

	<b>NAFLD fibrosis score &gt; 0.676, n (%)</b>	<b>Fibrosis-4 &gt; 2.67, n (%)</b>	<b>AST platelet ratio index <math>\geq</math> 1.0, n (%)</b>
Non-alcoholic fatty liver disease	2950 (56.2)	2820 (31.3)	619 (30.0)
Alcohol related liver disease	680 (12.9)	1620 (18.0)	661 (32.0)
Viral hepatitis	39 (0.7)	87 (1.0)	63 (3.1)
Autoimmune and biliary liver disease	32 (0.6)	67 (0.7)	32 (1.6)
Hemochromatosis	19 (0.4)	31 (0.3)	10 (0.5)
Other (vascular, drug-induced, inherited liver disease)	2 (0.04)	6 (0.1)	3 (0.1)
No clearly identifiable cause of liver disease	1531 (29.1)	4374 (48.6)	676 (32.8)

NAFLD, Non-alcoholic fatty liver disease; AST, aspartate transaminase

**NAFLD:** HSI > 30 or ICD code for NAFLD (excluding people drinking > 140 grams per week (women) or > 210 grams per week (men), or UKBB or ICD code for alcohol excess, or a non-NAFLD causes of liver disease)

**ArLD:** People drinking at harmful levels (> 280 grams per week women, > 400 grams per week men), or ICD code for alcohol related liver disease, or alcohol dependency

**Viral hepatitis:** UKBB or ICD code for viral hepatitis

**Autoimmune and biliary liver disease:** UKBB or ICD code for autoimmune hepatitis, primary biliary cholangitis, or primary sclerosing cholangitis

**Hemochromatosis:** UKBB or ICD code for haemochromatosis

**Other:** UKBB or ICD code for vascular, drug-induced or inherited liver disease

**No identifiable cause:** Not meeting criteria for any of the above

**Table 3.** Association of the non-invasive tests of liver fibrosis with hospitalization or death from heart failure in a general population cohort

	Risk fibrosis	Participants	Events (fatal)	Median follow up (months)	Event rate	Univariate HR (95% CI)	Model 1 HR (95% CI)	Model 2 HR (95% CI)	Model 3 HR (95% CI)	Model 4 HR (95% CI)
<b>NAFLD fibrosis score</b>	Low	327,270	8248 (55)	123.8	2.19	1.00 Ref.	1.00 Ref.	1.00 Ref.	1.00 Ref.	1.00 Ref.
	Intermediate	81,190	3498 (27)	128.4	0.90	1.76 (1.70-1.83) ****	1.77 (1.7-1.85) ****	1.77 (1.69-1.85) ****	1.33 (1.26-1.4) ****	1.30 (1.24-1.37) ****
	High	5400	781 (14)	122.4	0.21	6.25 (5.81-6.73) ****	3.61 (3.35-3.89) ****	3.69 (3.39-4.01) ****	1.72 (1.56-1.9) ****	1.59 (1.47-1.78) ****
<b>Fibrosis-4 score</b>	Low	271,951	7514 (59)	126.8	1.95	1.00 Ref.	1.00 Ref.	1.00 Ref.	1.00 Ref.	1.00 Ref.
	Intermediate	132,683	4292 (29)	129.4	1.09	1.24 (1.19-1.29) ****	1.07 (1.03-1.12) ***	1.13 (1.08-1.18) ****	1.33 (1.26-1.4) ****	1.17 (1.12-1.23) ****
	High	9,226	721 (8)	120.9	0.20	3.23 (3.00-3.49) ****	1.66 (1.54-1.8) ****	1.82 (1.67-1.98) ****	1.72 (1.56-1.9) ****	1.69 (1.55-1.84) ****
<b>AST platelet ratio index</b>	Low	411,691	12366 (94)	126.1	3.22	1.00 Ref.	1.00 Ref.	1.00 Ref.	1.00 Ref.	1.00 Ref.
	High	2,169	161 (2)	129.1	0.04	2.68 (2.29-3.13) ****	2.28 (1.95-2.66) p ****	2.38 (2.00-2.82) ****	1.88 (1.58-2.23) ****	1.85 (1.56-2.19) ****

NAFLD, Non-alcoholic fatty liver disease; AST, aspartate transaminase; HR, hazard ratio; CI, confidence interval

\* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p <0.0001

**NAFLD fibrosis score:** low risk < -1.455 (< 0.12 if ≥ 65 yrs); intermediate risk - 1.455 – 0.676 (0.12-0.676 if ≥ 65 yrs); high risk > 0.676

**Fibrosis-4 score:** low risk < 1.3 (<2.0 if ≥ 65 yrs); intermediate risk 1.3-2.67 (2.0-2.67 if ≥ 65 yrs); high risk > 2.67

**AST platelet ratio index:** low risk < 1.0; high risk ≥ 1.0

**Multivariable model 1:** Adjusted for age, sex, deprivation, ethnicity

**Multivariable model 2:** Adjusted for age, sex, deprivation, ethnicity, alcohol (continuous), smoking

**Multivariable model 3:** Adjusted for age, sex, deprivation, ethnicity, alcohol (continuous), smoking, diabetes, waist circumference, hypertension, dyslipidemia

**Multivariable model 4:** Adjusted for age, sex, deprivation, ethnicity, alcohol (continuous), smoking, diabetes, waist circumference, hypertension, dyslipidemia baseline acute coronary syndrome, valve disease, cardiomyopathy

**Table 4.** Association of non-invasive markers of liver fibrosis with hospitalization or death from heart failure stratified according to *PNPLA3* and *TM6SF2* polymorphisms in a general population cohort (univariate analysis)

			NAFLD fibrosis score			Fibrosis-4 score			AST platelet ratio index	
			Low	Intermediate	High	Low	Intermediate	High	Low	High
<b><i>PNPLA3</i></b> (rs738409)	CC	No. cases HF	5150	2159	466	4790	2583	402	7697	78
		HR (95% CI)	1.00 Ref.	1.72 (1.64-1.81) ****	6.20 (5.64- 6.82) ****	1.00 Ref.	1.20 (1.14- 1.25) ****	2.99 (2.70- 3.31) ****	1.00 Ref.	2.68 (2.15-3.35) ****
	CG	No. cases HF	2690	1143	269	2386	1455	261	4046	56
		HR (95% CI)	0.96 (0.92-1.01)	1.74 (1.63-1.85) ****	5.90 (5.21- 6.67) ****	0.94 (0.89-0.98) **	1.21 (1.14- 1.29) ****	3.28 (2.89- 3.71) ****	0.97 (0.94-1.01)	2.20 (1.69-2.87) ****
	GG	No. cases HF	342	169	41	283	216	53	526	26
		HR (95% CI)	0.89 (0.80-0.99) *	1.89 (1.63-2.21) ****	7.67 (5.64-10.43) ****	0.84 (0.75-0.95) **	1.26 (1.10- 1.44) ***	4.02 (3.06- 5.26) ****	0.94 (0.86-1.02)	4.70 (3.20-6.90) ****
<b><i>TM6SF2</i></b> (rs58542926)	CC	No. cases HF	7000	2981	674	6388	3672	595	10,530	125
		HR (95% CI)	1.00 Ref.	1.75 (1.68-1.83) ****	6.28 (5.80- 6.80) ****	1.00 Ref.	1.24 (1.19- 1.29) ****	3.17 (2.91- 3.45) ****	1.00 Ref.	2.54 (2.13-3.03) ****
	CT	No. cases HF	1132	476	95	1025	561	117	1671	32
		HR (95% CI)	1.01 (0.95-1.07)	1.93 (1.76-2.12) ****	6.16 (5.03- 7.54) ****	1.00 (0.94-1.07)	1.26 (1.16- 1.38) ****	3.73 (3.10- 4.48) ****	1.01 (0.96-1.06)	3.52 (2.49-4.98) ****
	TT	No. cases HF	33	16	6	35	18	2	53	2
		HR (95% CI)	0.76 (0.54-1.08)	1.51 (0.93-2.47)	6.59 (2.96-14.67) ****	0.89 (0.64-1.24)	1.00 (0.63- 1.59)	1.17 (0.29- 4.67)	0.82 (0.63-1.08)	2.33 (0.58-9.33)

Grey shaded boxes represent risk alleles associated with an increased risk of liver fibrosis

NAFLD, Non-alcoholic fatty liver disease; AST, aspartate transaminase; HR, hazard ratio; CI, confidence interval; HF, heart failure.

\* p<0.05, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001

**NAFLD fibrosis score:** low risk < -1.455 (< 0.12 if ≥ 65 yrs); intermediate risk - 1.455 – 0.676 (0.12-0.676 if ≥ 65 yrs); high risk > 0.676

**Fibrosis-4 score:** low risk < 1.3 (<2.0 if ≥ 65 yrs); intermediate risk 1.3-2.67 (2.0-2.67 if ≥ 65 yrs); high risk > 2.67

**AST platelet ratio index:** low risk < 1.0; high risk ≥ 1.0

## References (max 50)

1. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of Liver Disease: 2023 Update. *J Hepatol.* 2023;0:S0168-8278(23)00194–0.
2. Roca-Fernandez A, Banerjee R, Thomaidis-Brears H, Telford A, Sanyal A, Neubauer S, Nichols TE, Raman B, McCracken C, Petersen SE, AB Ntusi N, Cuthbertson DJ, Lai M, Dennis A, Banerjee A. Liver disease is a significant risk factor for cardiovascular outcomes - a UK Biobank study. *J Hepatol.* 2023;S0168-8278(23)00420–8.
3. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology.* 2018;67:123–133.
4. Targher G, Tilg H, Byrne CD. NAFLD: a multisystem disease requiring a multidisciplinary and holistic approach. *Lancet Global Health.* 2021;6:578–588.
5. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. *J Hepatol.* 2016;65:589–600.
6. Simon TG, Roelstraete B, Hagström H, Sundström J, Ludvigsson JF. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort. *Gut.* 2021;gutjnl-2021-325724.
7. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. *Lancet.* 2018;391:1513–23.
8. Fudim M, Zhong L, Patel K V., Khera R, Abdelmalek MF, Diehl AM, McGarrah RW, Molinger J, Moylan CA, Rao VN, Wegermann K, Neeland IJ, Halm EA, Das SR, Pandey A. Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries. *J Am Heart Assoc.* 2021;10:e021654.
9. Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, Bertolini L, Valbusa F, Barbieri E, Zoppini G, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. *PLoS One.* 2015;10:e0135329.
10. Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. *Gut.* 2022;72:372–380.
11. Ng CH, Lim WH, Hui Lim GE, Hao Tan DJ, Syn N, Muthiah MD, Huang DQ, Loomba R. Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology.* 2022;21:931-939.e5.
12. Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, Haas J, Berghold A, Bataller R, Stauber RE. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. *J Hepatol.* 2017;66:610–618.
13. Baratta F, Pastori D, Angelico F, Balla A, Paganini AM, Cocomello N, Ferro D, Violi F, Sanyal AJ, Del Ben M. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study. *Clinical Gastroenterology and Hepatology.* 2020;18:2324-2331.e4.
14. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. *Hepatology.* 2013;57:1357–1365.

15. Valenti L, Al-Serri A, Daly AK, Enrico Galmozzi, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviario G, Vanni E, Bugianesi E, Maggioni M, LudovicaFracanzani A, Fargion S, Day CP. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. *Hepatology*. 2010;51:1209–1217.
16. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. *Hepatology*. 2010;52:894–903.
17. Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JBS, Allison MED, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. *Nat Commun*. 2014;5:4309.
18. Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S, Pelusi S, Montalcini T, Alisi A, Maggioni M, Kärjä V, Borén J, Kärkelä P, Di Marco V, Xing C, Nobili V, Dallapiccola B, Craxi A, Pihlajamäki J, Fargion S, Sjöström L, Carlsson LM, Romeo S, Valenti L. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. *Hepatology*. 2015;61:506–514.
19. Kupcinskas J, Valantiene I, Varkalaitė G, Steponaitiene R, Skieceviciene J, Sumskiene J, Petrenkiene V, Kondrackiene J, Kiudelis G, Lammert F, Kupcinskas L. PNPLA3 and RNF7 Gene Variants are Associated with the Risk of Developing Liver Fibrosis and Cirrhosis in an Eastern European Population. *J Gastrointest Liver Dis*. 2017;26:37–43.
20. Tian C, Stokowski RP, Kershenovich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. *Nat Genet*. 2010;42:21–23.
21. Buch S, Stickel F, Trépo E, Way M, Herrmann A, Nischalke HD, Brosch M, Rosendahl J, Berg T, Ridinger M, Rietschel M, McQuillin A, Frank J, Kiefer F, Schreiber S, Lieb W, Soyka M, Semmo N, Aigner E, Datz C, Schmelz R, Brückner S, Zeissig S, Stephan AM, Wodarz N, Devière J, Clumeck N, Sarrazin C, Lammert F, Gustot T, Deltenre P, Völzke H, Lerch MM, Mayerle J, Eyer F, Schafmayer C, Cichon S, Nöthen MM, Nothnagel M, Ellinghaus D, Huse K, Franke A, Zopf S, Hellerbrand C, Moreno C, Franchimont D, Morgan MY, Hampe J. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. *Nat Genet*. 2015;47:1443–1448.
22. Trépo E, Gustot T, Degré D, Lemmers A, Verset L, Demetter P, Ouziel R, Quertinmont E, Vercruysse V, Amininejad L, Deltenre P, Le Moine O, Devière J, Franchimont D, Moreno C. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. *J Hepatol*. 2011;55:906–912.
23. Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, Lemmers A, Berthillon P, Amininejad L, Chevallier M, Schlué J, Kreipe H, Devière J, Manns M, Trépo C, Sninsky J, Wedemeyer H, Franchimont D, Moreno C. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. *Hepatology*. 2011;54:60–69.
24. Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D, Emdin C, Alam D, Alves AC, Amouyel P, Angelantonio E DI, Arveiler D, Assimes TL, Auer PL, Baber U, Ballantyne CM, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen YDI, Chowdhury R, Christensen C, Chu

- AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dubé MP, Ebeling T, Eiriksdottir G, Esko T, Farmaki AE, Feitosa MF, Ferrario M, Ferrieres J, Ford I, Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche LG, Frossard P, Fuster V, Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, Groop L, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin MR, Jensen GB, Jørgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera A V., Klarin D, Koistinen HA, Kooner JS, Kooperberg C, Kuulasmaa K, Kuusisto J, et al. Exome-wide association study of plasma lipids in >300,000 individuals. *Nature Genetics* 2017 49:12. 2017;49:1758–1766.
25. About UK Biobank, <http://www.ukbiobank.ac.uk/about-biobank-uk/>.
  26. UKBB self-reported non-cancer illness codes, <https://biobank.ctsu.ox.ac.uk/crystal/field.cgi?id=20002>.
  27. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S. Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M, APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. 2006;43:1317–1325.
  28. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology*. 2007;45:846–854.
  29. Wai C, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS-F. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*. 2003;38:518–526.
  30. Mackenbach JP. Health and deprivation. Inequality and the North: by P. Townsend, P. Phillimore and A. Beattie (eds.) Croom Helm Ltd, London, 1987 221 pp., ISBN 0-7099-4352-0. *Health Policy (New York)*. 1988;10:207.
  31. Von Elm E, Altman D, Egger M, Pocock S, Gotsche P, Vandenbroucke J. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *BMJ*. 2007;335:806-808.
  32. Lee J-H, Kim D, Kim HJ, Lee C-H, Yang JI, Kim W, Kim YJ, Yoon J-H, Cho S-H, Sung M-W, Hyo-Suk Lee. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. *Digestive and Liver Disease*. 2010;42:503–8.
  33. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D, Delaneau O, O’Connell J, Cortes A, Welsh S, Young A, Effingham M, McVean G, Leslie S, Allen N, Donnelly P, Marchini J. The UK Biobank resource with deep phenotyping and genomic data. *Nature* 2018 562:7726. 2018;562:203–209.
  34. Ostovaneh M, Ambale-Venkatesh B, Fuji T, Bakhshi H, Shah NR, Murthy V, Tracy R, Guallar E, Wu C, Bluemke D, Lima J. Association of Liver Fibrosis With Cardiovascular Diseases in the General Population: The Multi-Ethnic Study of Atherosclerosis (MESA). *Circ Cardiovasc Imaging*. 2018;11:e007241.
  35. Hydes TJ, Kennedy OJ, Buchanan R, Cuthbertson DJ, Parkes J, Fraser SDS, Roderick P. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank. *BMC Medicine* 2023 21:1. 2023;21:1–13.
  36. Park J, Kim G, Kim H, Lee J, Lee Y Bin, Jin SM, Hur KY, Kim JH. The association of hepatic steatosis and fibrosis with heart failure and mortality. *Cardiovasc Diabetol*. 2021;20:1–14.

37. Borén J, Adiels M, Björnson E, Matikainen N, Söderlund S, Rämö J, Ståhlman M, Ripatti P, Ripatti S, Palotie A, Mancina RM, Hakkarainen A, Romeo S, Packard CJ, Taskinen MR. Effects of TM6SF2 E167K on hepatic lipid and very low-density lipoprotein metabolism in humans. *JCI Insight* [Internet]. 2020 [cited 2023 Aug 22];5. Available from: [/pmc/articles/PMC7819740/](https://pubmed.ncbi.nlm.nih.gov/32819740/)
38. Martínez-Arranz I, Bruzzone C, Noureddin M, Gil-Redondo R, Mincholé I, Bizkarguenaga M, Arretxe E, Iruarizaga-Lejarreta M, Fernández-Ramos D, Lopitz-Otsoa F, Mayo R, Embade N, Newberry E, Mittendorf B, Izquierdo-Sánchez L, Smid V, Arnold J, Iruzubieta P, Pérez Castaño Y, Krawczyk M, Marigorta UM, Morrison MC, Kleemann R, Martín-Duce A, Hayardeny L, Vitek L, Bruha R, Aller de la Fuente R, Crespo J, Romero-Gomez M, Banales JM, Arrese M, Cusi K, Bugianesi E, Klein S, Lu SC, Anstee QM, Millet O, Davidson NO, Alonso C, Mato JM. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. *Hepatology*. 2022;76:1121.
39. Packer M. Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. *Am J Med*. 2020;133:170–177.
40. Yan T, Zhu S, Yin X, Xie C, Xue J, Zhu M, Weng F, Zhu S, Xiang B, Zhou X, Liu G, Ming Y, Zhu K, Wang C, Guo C. Burden, Trends, and Inequalities of Heart Failure Globally, 1990 to 2019: A Secondary Analysis Based on the Global Burden of Disease 2019 Study. *J Am Heart Assoc*. 2023;12:27852.
41. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. *The Lancet*. 2018;391:572–580.
42. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, Nichol G, Pham M, Piña IL, Trogon JG. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. *Circ Heart Fail*. 2013;6:606–619.
43. Brown E, Hydes T, Hamid A, Cuthbertson D. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. *Clin Ther*. 2021;43:1476–150.
44. Dobbie LJ, Kassab M, Davison AS, Grace P, Cuthbertson DJ, Hydes TJ. Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. *J Clin Med*. 2021;10:5755.
45. Innes H, Morling JR, Buch S, Hamill V, Stickel F, Guha IN. Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. *J Hepatol*. 2022;77:365–376.
46. Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract*. 2022;28:528–562.
47. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64:1388–1402.
48. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018;67:328–357.



49. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. *Gastroenterology*. 2005;128:1898–1906.
50. Mózes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, Paternostro R, Stauber RE, Holleboom AG, van Dijk A-M, Mak AL, Boursier J, de Saint Loup M, Shima T, Bugianesi E, Gaia S, Armandi A, Shalimar, Lupşor-Platon M, Wong VW-S, Li G, Wong GL-H, Cobbold J, Karlas T, Wiegand J, Sebastiani G, Tsochatzis E, Liguori A, Yoneda M, Nakajima A, Hagström H, Akbari C, Hirooka M, Chan W-K, Mahadeva S, Rajaram R, Zheng M-H, George J, Eslam M, Petta S, Pennisi G, Viganò M, Ridolfo S, Aithal GP, Palaniyappan N, Lee DH, Ekstedt M, Nasr P, Cassinotto C, de Lédinghen V, Berzigotti A, Mendoza YP, Noureddin M, Truong E, Fournier-Poizat C, Geier A, Martic M, Tuthill T, Anstee QM, Harrison SA, Bossuyt PM, Pavlides M, Anstee QM, Daly AK, Govaere O, Cockell S, Tiniakos D, Bedossa P, Burt A, Oakley F, Cordell HJ, Day CP, Wonders K, Missier P, McTeer M, Vale L, Oluboyede Y, Breckons M, Bossuyt PM, Zafarmand H, Vali Y, Lee J, Nieuwdorp M, Holleboom AG, Verheij J, Ratziu V, Clément K, Patino-Navarrete R, Pais R, Paradis V, Schuppan D, Schattenberg JM, Surabattula R, Myneni S, Straub BK, Vidal-Puig T, Vacca M, Rodrigues-Cuenca S, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. *Lancet Gastroenterol Hepatol*. 2023;0:S2468-1253(23)00141–3.





Figure 1. Study flow chart

**Figure 2.** Hazard ratios and 95% confidence intervals for the association of non-invasive markers of liver fibrosis and hospitalization or death due to heart failure following full multivariable adjustment in a general population cohort



**Figure 3.** Hazard ratios and 95% confidence intervals for the association of combined non-invasive markers of liver fibrosis and hospitalization or death due to heart failure following full multivariable adjustment in a general population cohort

